Health and Fitness Health and Fitness
Thu, March 31, 2011
[ Thu, Mar 31st 2011 ] - Market Wire
AIB Capital Update
[ Thu, Mar 31st 2011 ] - Market Wire
Pacific WebWorks Update
[ Thu, Mar 31st 2011 ] - Market Wire
Sirona Biochem Acquires TFChem

AVEO Pharmaceuticals, Inc. to Present at the Leerink Swann Cancer Roundtable Conference


Published on 2011-03-31 03:40:49 - Market Wire
  Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to participate in a panel titled aProstate and GU Cancersa at 12:15 p.m. (EDT), as well as present a corporate overview on AVEO at 1:15 p.m. (EDT), at the Leerink Swann Cancer Roundtable conference on Thursday, April 7, 2011 at the Roosevelt Hotel in New York City.

A live webcast of AVEO's presentation can be accessed by visiting the investors section of the company's website at investor.aveopharma.com. A replay of the webcast will be archived on the AVEO website for two weeks following the presentation.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patientsa™ lives. The companya™s lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEOa™s second most advanced product candidate, ficlatuzumab (AV-299), is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEOa™s proprietary Human Response Platforma" is designed to offer the company a unique advantage in cancer drug development and has provided a discovery engine for multiple therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the companya™s website at www.aveopharma.com.